Researchers show that GARP2 accelerates retinal degeneration in mice, and have made an important step toward creating a standardized nomenclature between mice and humans for a measurement of retinal degeneration.
The US Food & Drug Administration has granted GenSight’s developing drug, GS030, Orphan Drug Disease Designation for the treatment of retinitis pigmentosa.
A novel gene-editing method has been found to partially restore sight in rats bred with RP.
A stem cell-based transplantation approach that restores vision in blind mice moves closer to being tested in patients with end-stage retinal degeneration, according to a study published January 10 in Stem Cell Reports.
The US Food & Drug administration has granted orphan drug designation (ODD) to MeiraGTx’s adeno-associated virus (AAV)-mediated gene therapy product candidate for treatment of X-linked retinitis pigmentosa (XLRP).
Ten people with an inherited form of blindness will be fitted with retinal implants in a procedure funded by NHS England.
Eight patients with retinitis pigmentosa have received a stem cell injection in a 28-person safety study.
The Guardian reports blind animals have had their vision partially restored using a DNA editing technique that scientists say could in future be applied to a range of genetic diseases.
A patient with retinitis pigmentosa has reported that he could differentiate between light and dark for the first time in five years following the successful implant and activation of the IRIS II® bionic vision system, at Moorfields Eye Hospital NHS Foundation Trust in London.
Researchers have made a breakthrough in understanding what happens to the human brain after someone goes blind. The study out of the University of Pisa, Italy, found that the adult brain can actually learn to “see again” after a person went totally blind.